NCI-H1975Homo sapiens (Human)Cancer cell line

Also known as: NCIH1975, H-1975, H1975

🤖 AI SummaryBased on 6 publications

Quick Overview

Human non-small cell lung cancer cell line with EGFR mutations

Detailed Summary

The NCI-H1975 cell line is a human non-small cell lung cancer (NSCLC) cell line derived from a pleural effusion of a patient with lung adenocarcinoma. It is characterized by the presence of the EGFR L858R mutation and is commonly used in research related to EGFR tyrosine kinase inhibitors (TKIs). This cell line has been utilized in studies investigating drug resistance mechanisms, particularly in the context of osimertinib (AZD9291) resistance. NCI-H1975 cells exhibit specific molecular features that make them valuable for studying the efficacy of targeted therapies and understanding the genetic basis of cancer progression. The cell line is also used in proteomic and genomic studies to identify potential biomarkers and therapeutic targets.

Research Applications

EGFR tyrosine kinase inhibitor resistance studiesOsimertinib resistance mechanismsProteomic profilingGenomic analysisTargeted therapy development

Key Characteristics

EGFR L858R mutationUsed in drug resistance researchSuitable for targeted therapy studies
Generated on 6/17/2025

Basic Information

Database IDCVCL_1511
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age CategoryUnknown
SexFemale

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000587_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg273His (c.818G>A)Homozygous-Unknown, PubMed=16264262
MutationSimplePIK3CAp.Gly118Asp (c.353G>A)Heterozygous-from parent cell line NCI-H1975
MutationSimpleEGFRp.Leu858Arg (c.2573T>G)UnspecifiedIn 10% of cellsPubMed=31882684
MutationSimpleEGFRp.Thr790Met (c.2369C>T)UnspecifiedAcquired during resistance selection processPubMed=31882684

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D10S1248
13
D12S391
17
D13S317
10,13
D16S539
9,12
D18S51
13
D19S433
15,15.2
D1S1656
14,15
D21S11
28
D22S1045
14,15
D2S1338
17
D2S441
10,11
D3S1358
14,15
D5S818
11,12
D7S820
8
D8S1179
13
FGA
21,24
Penta D
12,13
Penta E
12,16
TH01
7
TPOX
8,11
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Potential utility of a 4th-generation EGFR-TKI and exploration of resistance mechanisms -- an in vitro study.

Mitsudomi T., Tsutani Y.

Biomedicines 12:1412.1-1412.13(2024).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Proteomic and ultrastructural analysis of Clara cell and type II alveolar epithelial cell-type lung cancer cells.

Hou W.-L., Chang M., Liu X.-F., Hu L.-S., Hua S.-C.

Transl. Cancer Res. 9:565-576(2020).

Comparative proteogenomics profiling of non-small and small lung carcinoma cell lines using mass spectrometry.

Wu J.-Y., Hao Z.-F., Ma C., Li P.-F., Dang L.-Y., Sun S.-S.

PeerJ 8:e8779.1-e8779.19(2020).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.

Jimenez C.R.

J. Proteomics 196:106-119(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.

Tang Z.-H., Jiang X.-M., Guo X., Fong C.M.V., Chen X.-P., Lu J.-J.

Oncotarget 7:81598-81610(2016).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.

Chen Y.-J.

Anal. Chem. 87:12016-12023(2015).

Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.

Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.

J. Proteome Res. 14:3658-3669(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.

Lv S.

Mol. Med. Rep. 11:2767-2774(2015).

The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.

Wang J., Wei H., Zhao B.-X., Li M., Lv W.-P., Lv L., Song B., Lv S.

J. Mol. Histol. 45:641-652(2014).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Lack of direct association between EGFR mutations and ER beta expression in lung cancer.

Onitsuka T., Uramoto H., Tanaka F.

Anticancer Res. 31:855-860(2011).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Systems-level modeling of cancer-fibroblast interaction.";

Finn S.P., Loda M., Mahmood U., Ramaswamy S.

PLoS ONE 4:E6888-E6888(2009).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Takada M., Fukuoka M., Nakagawa K.

Cancer Res. 67:2046-2053(2007).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Web Resources